Ixaltis SA

Founded in 2012 in Toulouse, France, Ixaltis SA specializes in pharmaceutical development, particularly for genitourinary and renal conditions. The company has secured EUR 390,000 in Series A funding as of February 2022, which aligns with its ongoing development and market strategies. The CEO is Roberto Gradnik. Ixaltis specializes in the development of innovative pharmaceutical products targeting genitourinary and renal diseases.

The company's core product offering includes Litoxetine (IXA-001), developed to address unmet medical needs in treating disorders of the urogenital tract. Additionally, Ixaltis is advancing two other compounds, IXA-002 and IXA-003, aimed at related indications, catering to healthcare providers and institutions involved in urology and renal care. In 2019, Ixaltis reported revenue of EUR 671. 9 mn, reflecting its transactional structure that likely includes partnerships with healthcare providers and pharmaceutical wholesalers for its products.

The revenue model may involve licensing agreements for the development and distribution of its compounds, including Litoxetine. Ixaltis plans to utilize the EUR 390,000 raised in Series A funding from February 2022 to support the development of its products, particularly focusing on Litoxetine. The company is also exploring opportunities for expansion into new markets and regions, aiming to establish partnerships and collaborations with healthcare institutions globally.